NM_000251.3(MSH2):c.816G>T (p.Ala272=) AND Hereditary cancer-predisposing syndrome
- Germline classification:
- Likely benign (2 submissions)
- Last evaluated:
- Mar 3, 2024
- Review status:
- Somatic classification
of clinical impact: - None
- Review status:
- Somatic classification
of oncogenicity: - None
- Review status:
- Record status:
- current
- Accession:
- RCV000581331.11
Allele description [Variation Report for NM_000251.3(MSH2):c.816G>T (p.Ala272=)]
NM_000251.3(MSH2):c.816G>T (p.Ala272=)
Condition(s)
- Name:
- Hereditary cancer-predisposing syndrome
- Synonyms:
- Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
- Identifiers:
- MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672
-
N-acetylneuraminate epimerase [Yersinia rohdei]
N-acetylneuraminate epimerase [Yersinia rohdei]gi|755392906|gnl|LANL|CH64_268|gb|A 44.1|Protein
-
LOC114564501 [Perca flavescens]
LOC114564501 [Perca flavescens]Gene ID:114564501Gene
-
Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systemat...
Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...Assertion and evidence details
Last Updated: Oct 13, 2024